Intramuscular (IM) rabies post-exposure prophylaxis + Intradermal (ID) rabies post-exposure prophylaxis
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rabies Post-exposure Prophylaxis
Conditions
Rabies Post-exposure Prophylaxis
Trial Timeline
Jul 15, 2020 → Apr 30, 2022
NCT ID
NCT05684185About Intramuscular (IM) rabies post-exposure prophylaxis + Intradermal (ID) rabies post-exposure prophylaxis
Intramuscular (IM) rabies post-exposure prophylaxis + Intradermal (ID) rabies post-exposure prophylaxis is a pre-clinical stage product being developed by Sanofi for Rabies Post-exposure Prophylaxis. The current trial status is completed. This product is registered under clinical trial identifier NCT05684185. Target conditions include Rabies Post-exposure Prophylaxis.
What happened to similar drugs?
2 of 15 similar drugs in Rabies Post-exposure Prophylaxis were approved
Approved (2) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05684185 | Pre-clinical | Completed |
Competing Products
20 competing products in Rabies Post-exposure Prophylaxis